The first evaluable patient in Cohort 2 (Patient 6) demonstrated a clear dose response, and early MyBP-C expression increased by 14% after only 12 weeks post-dose. Of note, Patient 6 had a greater ...

A rare initiative that bears the Crankstart name is the Crankstart Scholarship program unveiled in April. It aims to provide ...

In a time when programs for the arts are a target for federal cuts, Bay Area programs are trying to find ways to thrive.

Development of a novel RNA biomarker for prostate cancer detection using seminal fluid and mismatched opioid prescriptions following urologic surgery are among the topics being presented by UCSF ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, ...

Bisnow's San Francisco Multifamily & Affordable Housing Conference will explore the housing market’s recovery, new ...

CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 ...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced updates to its Board of Directors and executive leadership team.

Leadership brings experience in company building, advancing late-stage clinical programs, and deep understanding of cardiovascular drug developmentCompany intends to rapidly advance BHB-1893 into late ...

From tumor profiling to CAR-T optimization, AI is accelerating discovery and decision-making in immuno-oncology. PICI researchers are leveraging multimodal data and large language models to predict ...

Details of the TN-201 clinical data presentation are as follows: ...

Anti-immigration organisations and liberal economic groups alike have long attacked H-1B visas as a tool for replacing US employees with lower-paid foreign ones.